KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash from Investing Activities (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Cash from Investing Activities for 9 consecutive years, with $165.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 18.32% year-over-year to $165.0 million, compared with a TTM value of $737.0 million through Dec 2025, down 6.94%, and an annual FY2025 reading of $737.0 million, down 6.94% over the prior year.
  • Cash from Investing Activities was $165.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $135.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $508.0 million in Q1 2021 and bottomed at $135.0 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is $233.8 million, with a median of $192.5 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities surged 101.59% in 2021, then tumbled 68.31% in 2022.
  • Year by year, Cash from Investing Activities stood at $246.0 million in 2021, then plummeted by 31.71% to $168.0 million in 2022, then surged by 79.17% to $301.0 million in 2023, then crashed by 32.89% to $202.0 million in 2024, then dropped by 18.32% to $165.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for TEVA at $165.0 million in Q4 2025, $135.0 million in Q3 2025, and $236.0 million in Q2 2025.